Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001493152-26-010236

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Mar 16, 2026 4.52M sh
Shares Diluted Q1 2026 · Jan 31, 2026 4.48M sh
Shares Diluted Q1 2026 · Jan 31, 2025 4.46M sh
Operating Cash Flow Q1 2026 · Jan 31, 2026 −$1.11M
Operating Cash Flow Q1 2026 · Jan 31, 2025 −$428.34K
Long Term Debt Q1 2026 · Jan 31, 2026 $9.43M
Long Term Debt Q1 2026 · Oct 31, 2025 $8.99M
Short Term Debt Q1 2026 · Jan 31, 2026 $593.75K
Short Term Debt Q1 2026 · Oct 31, 2025 $593.75K
Stockholders Equity Q1 2026 · Jan 31, 2026 −$16.15M
Stockholders Equity Q1 2026 · Oct 31, 2025 −$16.33M
Stockholders Equity Q1 2026 · Jan 31, 2025 −$9.91M
Stockholders Equity Q1 2026 · Oct 31, 2024 −$9M
Current Liabilities Q1 2026 · Jan 31, 2026 $5.42M
Current Liabilities Q1 2026 · Oct 31, 2025 $5.68M
Total Liabilities Q1 2026 · Jan 31, 2026 $21.04M
Total Liabilities Q1 2026 · Oct 31, 2025 $21.26M
Current Assets Q1 2026 · Jan 31, 2026 $868.3K
Current Assets Q1 2026 · Oct 31, 2025 $862.1K
Total Assets Q1 2026 · Jan 31, 2026 $4.89M
Total Assets Q1 2026 · Oct 31, 2025 $4.93M
Eps Diluted Q1 2026 · Jan 31, 2026 −$0.26
Eps Diluted Q1 2026 · Jan 31, 2025 −$0.64
Eps Basic Q1 2026 · Jan 31, 2026 −$0.26
Eps Basic Q1 2026 · Jan 31, 2025 −$0.64
Sga Expense Q1 2026 · Jan 31, 2026 $1.33M
Sga Expense Q1 2026 · Jan 31, 2025 $2.13M
Rd Expense Q1 2026 · Jan 31, 2026 $169.22K
Rd Expense Q1 2026 · Jan 31, 2025 $73.88K
Net Income Q1 2026 · Jan 31, 2026 −$1.11M
Net Income Q1 2026 · Jan 31, 2025 −$2.83M
Operating Income Q1 2026 · Jan 31, 2026 −$1.19M
Operating Income Q1 2026 · Jan 31, 2025 −$1.85M
Gross Profit Q1 2026 · Jan 31, 2026 $411.95K
Gross Profit Q1 2026 · Jan 31, 2025 $356.78K
Cost Of Revenue Q1 2026 · Jan 31, 2026 $117.46K
Cost Of Revenue Q1 2026 · Jan 31, 2025 $93.09K
Revenue Q1 2026 · Jan 31, 2026 $529.42K
Revenue Q1 2026 · Jan 31, 2025 $449.87K